Alphamab Oncology
HKEX:9966
Income Statement
Earnings Waterfall
Alphamab Oncology
Income Statement
Alphamab Oncology
| Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||
| Interest Expense |
2
|
8
|
11
|
11
|
13
|
17
|
13
|
9
|
11
|
10
|
9
|
7
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
146
N/A
|
200
+37%
|
167
-16%
|
250
+50%
|
219
-12%
|
256
+17%
|
640
+150%
|
786
+23%
|
|
| Gross Profit | |||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
(3)
|
(18)
|
(44)
|
(63)
|
(55)
|
(53)
|
(60)
|
(61)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
143
N/A
|
182
+27%
|
123
-33%
|
187
+53%
|
164
-13%
|
203
+24%
|
580
+186%
|
725
+25%
|
|
| Operating Income | |||||||||||||
| Operating Expenses |
(822)
|
(933)
|
(365)
|
(460)
|
(540)
|
(533)
|
(531)
|
(499)
|
(469)
|
(466)
|
(466)
|
(527)
|
|
| Selling, General & Administrative |
(118)
|
(134)
|
(78)
|
(76)
|
(77)
|
(83)
|
(87)
|
(76)
|
(79)
|
(81)
|
(75)
|
(74)
|
|
| Research & Development |
(167)
|
(245)
|
(331)
|
(429)
|
(481)
|
(466)
|
(468)
|
(447)
|
(408)
|
(407)
|
(404)
|
(463)
|
|
| Other Operating Expenses |
(537)
|
(554)
|
44
|
45
|
19
|
16
|
24
|
24
|
18
|
22
|
13
|
10
|
|
| Operating Income |
(822)
N/A
|
(933)
-13%
|
(365)
+61%
|
(460)
-26%
|
(397)
+14%
|
(351)
+11%
|
(408)
-16%
|
(312)
+24%
|
(306)
+2%
|
(263)
+14%
|
114
N/A
|
198
+74%
|
|
| Pre-Tax Income | |||||||||||||
| Interest Income Expense |
26
|
79
|
(62)
|
(132)
|
(15)
|
60
|
83
|
94
|
96
|
48
|
54
|
36
|
|
| Non-Reccuring Items |
(37)
|
(24)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
(1)
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
| Pre-Tax Income |
(833)
N/A
|
(877)
-5%
|
(428)
+51%
|
(592)
-38%
|
(412)
+30%
|
(292)
+29%
|
(326)
-11%
|
(218)
+33%
|
(211)
+4%
|
(216)
-2%
|
166
N/A
|
233
+40%
|
|
| Net Income | |||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(833)
|
(877)
|
(428)
|
(592)
|
(412)
|
(292)
|
(326)
|
(218)
|
(211)
|
(216)
|
166
|
233
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(833)
N/A
|
(877)
-5%
|
(428)
+51%
|
(592)
-38%
|
(412)
+30%
|
(292)
+29%
|
(326)
-11%
|
(218)
+33%
|
(211)
+4%
|
(216)
-2%
|
166
N/A
|
233
+40%
|
|
| EPS (Diluted) |
-1.55
N/A
|
-0.94
+39%
|
-0.46
+51%
|
-0.63
-37%
|
-0.44
+30%
|
-0.31
+30%
|
-0.35
-13%
|
-0.23
+34%
|
-0.22
+4%
|
-0.22
N/A
|
0.17
N/A
|
0.23
+35%
|
|